Main menu



F2G is a world-leading UK and Austrian based biotech company, focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds, that act via a completely different mechanism than currently marketed agents. The company has a seasoned management team and Board and is backed by experienced, high-quality venture investors.

A Phase IIb open label study with the lead candidate, olorofim, is currently underway with sites in 6 countries across Europe, the USA and Australia. This study is recruiting patients with invasive aspergillosis, scedosporiosis and other rare and resistant mould infections, who are poorly-responsive to, resistant to or intolerant of currently-approved antifungal agents. Olorofim is being developed both as IV and oral formulations, for the treatment of adults and children with invasive mould infections.

Find us

Contact us

F2G Ltd
Lankro Way
United Kingdom
M30 0LX

Telephone | +44 (0)161 785 1270
Fax | +44 (0)161 785 1273
email |

Registered in England and Wales. Company Registration No. 03578625, VAT Reg No. 712680645.